Summary of Purpose
The FLAG1 study will assess the diagnostic performance of biomarkers Glutathion S-Transferase-π (GST-π) and Peroxyredoxin 1 (PRDX1) to identify cerebral infarction of less than 4,5 hours in a population of patients with neurological deficiency of less than 12 hours.Read More →
The following dates are available for this trial. Trial information last updated on 30 November 2017.
|1 Jan 2018||23 Nov 2017||1 Jan 2021||1 Jul 2021||1 Nov 2017||Unavailable|
|Start Date||First Received||1st Completion||Completion||Verification||Results|